6926-44-9

Basic information

• Product Name: Benzene, (2-azidoethyl)-
• Synonyms: Benzene, (2-azidoethyl)-
• CAS NO: 6926-44-9
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 0
• Mol File: 6926-44-9.mol
• Article Data: 104

Chemical Properties

• Boiling Point: 68 °C(Press: 0.5 Torr)
• Appearance: /
• CAS DataBase Reference: Benzene, (2-azidoethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, (2-azidoethyl)-(6926-44-9)
• EPA Substance Registry System: Benzene, (2-azidoethyl)-(6926-44-9)

Safety Data

• Hazardous Substances Data: 6926-44-9(Hazardous Substances Data)

Usage

Uses

(2-Azidoethyl)benzene is used as a reactant in the preparation of disubstituted triazoles via ruthenium-catalyzed cycloaddition of terminal alkynes with azides.

InChI:InChI=1/C8H9N3/c9-11-10-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2

Upstream product

• 103-63-9 1-phenyl-2-bromoethane 
• 60-12-8 2-phenylethanol 
• 4455-09-8 2-phenylethyl tosylate 
• 55419-66-4 trifluoroacetic acid 2-phenylethyl ester 
• 20020-27-3 2-phenylethyl mesylate 
• 1927-61-3 2-(2-phenylethoxy)tetrahydro-2H-pyran 
• 1246367-30-5 benzotriazol-1-yl-sulfonyl azide 
• 64-04-0 phenethylamine 
• 1266134-54-6 2-azido-1,3-dimethyl-4,5-dihydro-1H-imidazol-3-ium hexafluorophosphate (V) 
• 622-24-2 2-phenylethyl chloride 
• 122-78-1 phenylacetaldehyde 
• 17376-04-4 2-phenethyl iodide 

Downstream Products

• 64-04-0 phenethylamine 
• 15795-36-5 N,N-dimethyl-N'-phenethyl-formamidine 
• 28917-26-2 3-(1-phenethylamino-ethylidene)-dihydro-furan-2-one 
• 5460-60-6 N-phenethyl-2-phenylacetamide 
• 251350-20-6 N-phenethyl-heptanamide 
• 33542-82-4 N-phenethyl-N-(1'-phenylethyl)formamide 
• 41431-75-8 N-phenethyl-2-phenylpropanamide 
• 156-28-5 2-phenylethylamine hydrochloride 
• 1039487-29-0 8-((1-phenethyl-1H-1,2,3-triazol-5-yl)methyl)-1-phenyl-1,3,8-trispiro[4.5]decan-4-one 
• 1039487-33-6 17-(3-benzyl-3H-1,2,3-triazol-4-yl)-17-ethisterone 
• 1039487-57-4 4-ethyl-1-phenethyl-5-phenyl-1H-1,2,3-triazole 
• 1039487-59-6 5-ethyl-1-phenethyl-4-phenyl-1H-1,2,3-triazole 
• 1039487-55-2 2-(1-phenethyl-4-phenyl-1H-1,2,3-triazol-5-yl)propan-2-ol 
• 1039487-32-5 1-((3-phenethyl-3H-1,2,3-triazol-4-yl)methyl)-4-phenylpiperidine 

Relevant articles and documents

Controlling the selectivity of C-H activation in pyridinium triazolylidene iridium complexes: Mechanistic details and influence of remote substituents

Iridium complexes containing a triazolylidene ligand with an appended methylpyridinium site undergo either aromatic C(sp2)-H bond activation or exocyclic C(sp3)-H bond activation of the N-bound methyl group. The selectivity of these

Two-Step Protocol for Iodotrimethylsilane-Mediated Deoxy-Functionalization of Alcohols

We have developed a two-step protocol for iodotrimethylsilane-mediated deoxy-functionalization of primary and secondary alcohols to afford products containing a C?N, C?S, or C?O bond. In the first step the alcohol undergoes iodination with iodotrimethylsilane, and in the second, the iodine atom is replaced by a N, S, or O nucleophile. Compared with traditional Mitsunobu reaction, non-acidic pre-nucleophiles can be used, and the reaction proceeds with retention of configuration. This operationally simple, highly efficient protocol can be used for some natural products and small-molecule drugs containing hydroxy-group.

A general procedure for carbon isotope labeling of linear urea derivatives with carbon dioxide

Carbon isotope labeling is a traceless technology, which allows tracking the fate of organic compounds either in the environment or in living organisms. This article reports on a general approach to label urea derivatives with all carbon isotopes, including14C and11C, based on a Staudinger aza-Wittig sequence. It provides access to all aliphatic/aromatic urea combinations.

TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease without any effective treatment. Protein TDP-43 is a pathological hallmark of ALS in both sporadic and familiar patients. Post-translational modifications of TDP-43 promote its aggre